The relatively low-key asset might at least partly be responsible for Biocryst shares more than doubling since the start of December.
Merck & Co/Eisai’s Clear study results look better than Bristol/Exelixis’s Checkmate-9ER, but the big loser could be Pfizer.
Subgroup analysis of a confirmatory US study in bladder cancer suggests no benefit in female patients.
Will it be a new class of cancer drug or another failure for Novartis’s IL-1 inhibitor?
Promising early data with the group’s gene therapy put it ahead of Regenxbio for now.
Bladder cancer is the fourth tumour type to give Opdivo a phase III adjuvant win, and the extent of the survival benefit is impressive.
But how will the complex J&J bispecific antibody fare in a market where oral small molecules are the norm?
Full data show just how big a bust Keynote-598 is, though Bristol is unlikely to abandon hope.
But the unveiling of sotorasib’s registrational dataset shows that bulls should be cautious of Mirati's numerical advantage.